Chelsey B. Weatherill
Research Subjects
Chelsey B. Weatherill has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Michael J. Demeure
Hoag Family Cancer Institute, Newport Beach, CA 92663, USA
2 shared publications - Sourat Darabi
Hoag Family Cancer Institute, Hoag Presbyterian Hospital, Newport Beach, CA 92663, USA
2 shared publications Adriane L. Lombardo
1 shared publicationAnn M. Mauer
1 shared publicationBeth Y. Karlan
Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA
1 shared publicationBrenda Ramczyk
Advocate Health Midwest, Milwaukee, WI
1 shared publication
Latest Publications
- Open Access
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (11)
Cancer Risks Associated With Germline BARD1 Pathogenic/Likely Pathogenic Variants: A Multicenter Study of 445 Families
Purpose: To estimate the relative and absolute risks (ARs) for ovarian, prostate, male and female breast, pancreatic, biliary tract, and colorectal cancers associated with germline BARD1 pathogenic and likely pathogenic variants (PVs/LPVs) because these risks have not previously been reported from a genotype-first perspective. Methods: We performed a secondary retrospective analysis of multicenter data comprising 445 three-generation pedigrees with confirmed BARD1 PVs/LPVs from 25 institutions nationwide. Data were aggregated at the family-relatedness level. The risks were estimated using a Bayesian survival model that incorporated information from the Surveillance, Epidemiology, and End Results (SEER) Program. Results: We confirmed the previously established increased risk for female breast cancer (relative risk [RR] = 3.53; 95% CI, 1.95 to 5.81; posterior probability [PP] = 0.0040) and found positive associations with female pancreatic cancer (RR = 3.76 [95% CI, 2.16-7.25]; PP < .0001), male pancreatic cancer (RR = 2.89 [95% CI, 1.66 to 5.61]; PP < .0001), and prostate cancer (RR = 3.02 [95% CI, 1.95 to 4.71]; PP < .0001). The predictive ARs to age 85 were 41.84% (95% CI, 23.09 to 68.91) for female breast cancer, 4.80% (95% CI, 2.76 to 9.25) for female pancreatic cancer, 3.98% (95% CI, 2.29 to 7.73) for male pancreatic cancer, and 36.11% (95% CI, 23.29 to 56.29) for prostate cancer. Risk estimates suggest an association for male breast, ovarian, and female colorectal cancers; however, the clinical significance is unclear, and these findings warrant cautious interpretation. In contrast, we found no evidence of association for biliary tract cancer or male colorectal cancer. Conclusion: These results support BARD1 's association with female breast cancer and suggest associations with pancreatic and prostate cancers. These findings have potential implications for genetic counseling and personalized risk management for male and female BARD1 PV/LPV heterozygotes.
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (11)
Open AccessCancer Risks Associated With Germline BARD1 Pathogenic/Likely Pathogenic Variants: A Multicenter Study of 445 Families
Purpose: To estimate the relative and absolute risks (ARs) for ovarian, prostate, male and female breast, pancreatic, biliary tract, and colorectal cancers associated with germline BARD1 pathogenic and likely pathogenic variants (PVs/LPVs) because these risks have not previously been reported from a genotype-first perspective. Methods: We performed a secondary retrospective analysis of multicenter data comprising 445 three-generation pedigrees with confirmed BARD1 PVs/LPVs from 25 institutions nationwide. Data were aggregated at the family-relatedness level. The risks were estimated using a Bayesian survival model that incorporated information from the Surveillance, Epidemiology, and End Results (SEER) Program. Results: We confirmed the previously established increased risk for female breast cancer (relative risk [RR] = 3.53; 95% CI, 1.95 to 5.81; posterior probability [PP] = 0.0040) and found positive associations with female pancreatic cancer (RR = 3.76 [95% CI, 2.16-7.25]; PP < .0001), male pancreatic cancer (RR = 2.89 [95% CI, 1.66 to 5.61]; PP < .0001), and prostate cancer (RR = 3.02 [95% CI, 1.95 to 4.71]; PP < .0001). The predictive ARs to age 85 were 41.84% (95% CI, 23.09 to 68.91) for female breast cancer, 4.80% (95% CI, 2.76 to 9.25) for female pancreatic cancer, 3.98% (95% CI, 2.29 to 7.73) for male pancreatic cancer, and 36.11% (95% CI, 23.29 to 56.29) for prostate cancer. Risk estimates suggest an association for male breast, ovarian, and female colorectal cancers; however, the clinical significance is unclear, and these findings warrant cautious interpretation. In contrast, we found no evidence of association for biliary tract cancer or male colorectal cancer. Conclusion: These results support BARD1 's association with female breast cancer and suggest associations with pancreatic and prostate cancers. These findings have potential implications for genetic counseling and personalized risk management for male and female BARD1 PV/LPV heterozygotes.
- 17 October 2022
- Published by Wiley in Clinical Genetics
- Vol. 103 (2) , 231-235
Six case reports of NTHL1‐associated tumor syndrome further support it as a multi‐tumor predisposition syndrome
NTHL1-associated tumor syndrome (NATS) is an autosomal recessive condition characterized by an increased risk for colorectal polyposis and colorectal cancer (CRC). Only 46 case reports have been previously published. In a retrospective review, we analyzed the clinical histories of six patients found to have NATS after genetic counseling and testing. NATS appears to be associated with an increased risk for colorectal polyposis, CRC, female breast cancer, meningiomas, and endometrial cancer. Although research is limited, prior publications have reported a multi-tumor predisposition for individuals with biallelic pathogenic or likely pathogenic variants in NTHL1. Additional data are necessary to further define the cancer risks so affected individuals can be appropriately managed.
- 17 October 2022
- Published by Wiley in Clinical Genetics
- Vol. 103 (2) , 231-235
Six case reports of NTHL1‐associated tumor syndrome further support it as a multi‐tumor predisposition syndrome
NTHL1-associated tumor syndrome (NATS) is an autosomal recessive condition characterized by an increased risk for colorectal polyposis and colorectal cancer (CRC). Only 46 case reports have been previously published. In a retrospective review, we analyzed the clinical histories of six patients found to have NATS after genetic counseling and testing. NATS appears to be associated with an increased risk for colorectal polyposis, CRC, female breast cancer, meningiomas, and endometrial cancer. Although research is limited, prior publications have reported a multi-tumor predisposition for individuals with biallelic pathogenic or likely pathogenic variants in NTHL1. Additional data are necessary to further define the cancer risks so affected individuals can be appropriately managed.